Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.

Transplantation·1992

Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status.

Genomics·1992

Donor alloreactivity may predict acute graft-versus-host disease in HLA-matched bone marrow transplantation for leukemia in early remission.

European journal of haematology·1992

Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.

Bone marrow transplantation·1992

Is there a better way to deliver total body irradiation?

Bone marrow transplantation·1992

Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood·1991

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Immunohistochemical Expression of Tyrosine Kinase Receptors EGFR and CD117 in Canine Urothelial Carcinoma.

Veterinary sciences·2026

A Curated Phenotype-Linked HIV-1 Sequence Dataset for Machine Learning Approaches to Tropism Prediction, Disease Progression and Proviral Reservoir Studies.

Viruses·2026

Effects of Feline Herpesvirus Type 1 Vaccination on Clinical Disease, Viral Shedding, and Post-Vaccination Reactions: A Systematic Review and Exploratory Meta-Analysis.

Viruses·2026

Frequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta.

Viruses·2026

Impact of the COVID-19 Pandemic and Public Health Measures on Hepatitis C Treatment Initiation in Ontario, Canada.

Viruses·2026

HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis.

Viruses·2026

Related Experiment Videos

Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma

Related Concept Videos

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.

Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status.

Donor alloreactivity may predict acute graft-versus-host disease in HLA-matched bone marrow transplantation for leukemia in early remission.

Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.

Is there a better way to deliver total body irradiation?

Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Immunohistochemical Expression of Tyrosine Kinase Receptors EGFR and CD117 in Canine Urothelial Carcinoma.

A Curated Phenotype-Linked HIV-1 Sequence Dataset for Machine Learning Approaches to Tropism Prediction, Disease Progression and Proviral Reservoir Studies.

Effects of Feline Herpesvirus Type 1 Vaccination on Clinical Disease, Viral Shedding, and Post-Vaccination Reactions: A Systematic Review and Exploratory Meta-Analysis.

Frequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta.

Impact of the COVID-19 Pandemic and Public Health Measures on Hepatitis C Treatment Initiation in Ontario, Canada.

HPV6/11 Persistence and Treatment-Associated Immune Remodeling in Recurrent Respiratory Papillomatosis: A Cross-Cohort Transcriptomic Analysis.

Related Experiment Videos

Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma

Related Concept Videos

Related Articles